Q3 2025 Sumitomo Chemical Co Ltd Earnings Call Transcript
Key Points
- Core operating income for the third quarter improved significantly, with a profit of JPY60.1 billion compared to a loss of JPY113.9 billion in the same period last year.
- Sales revenue increased by JPY98 billion year over year, reaching JPY1,904.8 billion.
- The company achieved a net income attributable to owners of the parent of JPY28.6 billion, an improvement of JPY138.4 billion year on year.
- Sumitomo Pharma's core operating income saw a significant improvement of JPY116.2 billion year on year.
- Free cash flow was positive JPY197.5 billion, an improvement of JPY410.2 billion compared to the previous fiscal year.
- Non-recurring items posted losses, including Sumitomo Pharma's North America business restructuring cost of JPY14.8 billion and impairment loss of JPY5.5 billion.
- The essentials and green material segment reported a core operating income loss of JPY44.3 billion, despite an improvement year on year.
- The Advanced Medical Solutions segment saw a decline in core operating income by JPY1.8 billion year on year.
- The company faced a temporary loss of JPY23.8 billion related to the loan to Petro Rabigh.
- The forecast for the full year remains unchanged despite potential upside, indicating ongoing uncertainties and lower predictability.
As it is time to start, we will now begin the conference call for the presentation of the financial results for fiscal year 2024 third quarter. Thank you very much for your participation.
Today Mr. Sasaki, Managing Executive Officer will give a briefing on the financial results for FY 2024 third quarter later, he will be joined by Mr. Yamauchi, Executive Officer and General Manager of accounting department to take questions. We plan to conclude the call at 5:50.
Now, Mr. Sasaki over to you.
Thank you. I'm Sasaki from Sumitomo Chemical. Thank you very much for attending our conference call despite your busy schedule. I'd like to thank the investors and analysts for your daily understanding and support to our management.
I'd like to thank you all for that. Let me start with a briefing of the financial results for FY 2024 third quarter. Please turn to slide page 4. Before going to the details of financial results, I'd like to summarize some major points that I'd like
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
